InnovAge INNV is scheduled to release third-quarter fiscal 2026 results on May 05, after market close. In the last reported quarter, the company delivered an earnings surprise of 100.00%.
The company appears to have entered the second half of fiscal 2026 with strong operational momentum and improving financial visibility. While membership growth is likely to have remained solid, supported by successful Medicaid reinstatements and steady enrollment trends, some normalization is expected as prior tailwinds fade. At the same time, medical cost management and operational efficiencies are likely to have remained favorable, though seasonal pressures such as higher inpatient utilization could weigh modestly on margins.
So far this year, INNV’s shares have surged 60.3% against the industry’s fall of 11.6%. The S&P Index has gained 6.5% in the same period.
Image Source: Zacks Investment Research
Q3 Estimates
The Zacks Consensus Estimate for earnings is pegged at 6 cents per share, indicating an increase of 175% year over year.
The consensus mark for revenues is pinned at $234.5 million, implying growth of 7.5% from the prior-year reported figure.
Factors to Note
InnovAge’s upcoming quarterly performance is likely to have reflected continued operational momentum, though some normalization in margins and seasonal pressures could temper near-term upside following a strong first half. The company recently delivered double-digit revenue growth and a sharp improvement in profitability, driven by better execution across its PACE (Program of All-Inclusive Care for the Elderly) model and favorable rate dynamics.
At the consolidated level, revenue growth is expected to have remained healthy, supported by membership expansion and higher capitation rates. Recent strength has been aided by the successful reinstatement of participants who had previously lost Medicaid coverage, which boosted member months and reduced revenue reserves. However, as this tailwind normalizes, growth may increasingly depend on organic enrollment gains and retention improvements. Additionally, while Medicaid rates have been slightly favorable, the broader reimbursement environment remains subject to policy variability, particularly around Medicare risk adjustments.
From a cost perspective, medical cost management has emerged as a key driver of margin expansion. The company has demonstrated improved control over inpatient and skilled nursing utilization, alongside benefits from in-house pharmacy operations. These efficiencies are likely to have persisted, though seasonal factors — such as higher flu incidence and elevated inpatient admissions — could pressure medical costs in the near term.
Operationally, center-level productivity and SG&A discipline have improved meaningfully through restructuring and better workforce management, which is likely to have contributed to margin expansion. Still, management has indicated that the third quarter is likely to be typically softer due to enrollment seasonality and cost pressures, suggesting some moderation in profitability before reacceleration later in the year.
The census growth, participant retention, and continued improvements in revenue integrity will be critical. Initiatives around patient experience and reducing clinical variability could support longer-term growth and margin durability, though these benefits are likely to accrue gradually.
What the Zacks Model Unveils
Our proven model does not conclusively predict an earnings beat for Stryker this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the chances of an earnings beat. This is not the case here, as you will see below.
Earnings ESP: Earnings ESP, which represents the difference between the Most Accurate Estimate and the Zacks Consensus Estimate, is 0.00% for INNV. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter.
Zacks Rank: The company carries a Zacks Rank #3 at present.
InnovAge Holding Corp. Price and EPS Surprise
InnovAge Holding Corp. price-eps-surprise | InnovAge Holding Corp. Quote
Stocks Worth a Look
Here are some medical product stocks worth considering, as these have the right combination of elements to post an earnings beat this reporting cycle.
Microbot Medical MBOT has an Earnings ESP of +8.70% and a Zacks Rank of 2 at present.
MBOT’s earnings surpassed estimates in two of the trailing four quarters and missed twice, with the average surprise being 7.53%. The Zacks Consensus Estimate for MBOT’s first-quarter loss per share implies no change from the year-ago reported figure.
Henry Schein HSIC has an Earnings ESP of +0.28% and a Zacks Rank #3 at present. The company is slated to release first-quarter 2026 results on May 5.
HSIC’s earnings surpassed estimates in three of the trailing four quarters and missed once, with the average surprise being 2.14%. The Zacks Consensus Estimate for HSIC’s first-quarter EPS indicates an improvement of 4.4% from the year-ago reported figure.
IDEXX Laboratories IDXX has an Earnings ESP of +0.77% and a Zacks Rank of 3 at present. The company is slated to release first-quarter 2026 results on May 5.
IDXX’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 6.11%. The Zacks Consensus Estimate for IDXX’s first-quarter EPS indicates a gain 15.5% from the year-ago reported figure.
Zacks' Research Chief Names "Stock Most Likely to Double"
Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.
This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.
Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Henry Schein, Inc. (HSIC): Free Stock Analysis Report
IDEXX Laboratories, Inc. (IDXX): Free Stock Analysis Report
InnovAge Holding Corp. (INNV): Free Stock Analysis Report
Microbot Medical Inc. (MBOT): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).